Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand.

Higham EM, Wittrup KD, Chen J.

J Immunol. 2010 Apr 1;184(7):3394-400. doi: 10.4049/jimmunol.0903111. Epub 2010 Mar 3.

2.

CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells.

Fujita N, Kagamu H, Yoshizawa H, Itoh K, Kuriyama H, Matsumoto N, Ishiguro T, Tanaka J, Suzuki E, Hamada H, Gejyo F.

J Immunol. 2001 Nov 15;167(10):5678-88.

3.

Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.

Soong RS, Song L, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF.

PLoS One. 2014 Mar 24;9(3):e93162. doi: 10.1371/journal.pone.0093162. eCollection 2014.

4.

Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.

Lutz-Nicoladoni C, Wallner S, Stoitzner P, Pircher M, Gruber T, Wolf AM, Gastl G, Penninger JM, Baier G, Wolf D.

Immunol Cell Biol. 2012 Jan;90(1):130-4. doi: 10.1038/icb.2011.11. Epub 2011 Mar 8.

PMID:
21383769
5.

Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.

Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA.

Cancer Res. 2009 Aug 1;69(15):6256-64. doi: 10.1158/0008-5472.CAN-08-4516. Epub 2009 Jul 21. Retraction in: Cancer Res. 2016 Apr 15;76(8):2490.

6.

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.

Liu Y, Zhang X, Zhang W, Chen Z, Chan T, Ali K, Jia Z, Xiang J.

Cancer Gene Ther. 2002 Feb;9(2):202-8.

7.

Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.

Parameswaran S, Khalil M, Ahmed KA, Sharma RK, Xiang J.

Tumori. 2015 Nov-Dec;101(6):637-43. doi: 10.5301/tj.5000297. Epub 2015 May 15.

PMID:
25983089
8.

CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.

Nesbeth YC, Martinez DG, Toraya S, Scarlett UK, Cubillos-Ruiz JR, Rutkowski MR, Conejo-Garcia JR.

J Immunol. 2010 May 15;184(10):5654-62. doi: 10.4049/jimmunol.0903247. Epub 2010 Apr 16.

9.

In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.

Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS.

J Immunol. 2003 Jul 15;171(2):697-707.

10.
11.

CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L.

Price JD, Beauchamp NM, Rahir G, Zhao Y, Rieger CC, Lau-Kilby AW, Tarbell KV.

J Leukoc Biol. 2014 Feb;95(2):325-36. doi: 10.1189/jlb.0113013. Epub 2013 Sep 30.

12.
14.

Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.

Tian S, Liu Z, Donahue C, Falo LD Jr, You Z.

Mol Ther. 2012 Feb;20(2):432-42. doi: 10.1038/mt.2011.183. Epub 2011 Sep 20.

16.

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.

Hu HM, Winter H, Urba WJ, Fox BA.

J Immunol. 2000 Oct 15;165(8):4246-53.

17.

A CD40/CD40L feedback loop drives the breakdown of CD8(+) T-cell tolerance following depletion of suppressive CD4(+) T cells.

Muth S, Schütze K, Hain T, Yagita H, Schild H, Probst HC.

Eur J Immunol. 2014 Apr;44(4):1099-107. doi: 10.1002/eji.201343738. Epub 2014 Jan 20.

18.

Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.

Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tüting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD.

Cancer Res. 2011 Sep 1;71(17):5827-37. doi: 10.1158/0008-5472.CAN-11-0804. Epub 2011 Jul 11.

19.

Differential CD40/CD40L expression results in counteracting antitumor immune responses.

Murugaiyan G, Agrawal R, Mishra GC, Mitra D, Saha B.

J Immunol. 2007 Feb 15;178(4):2047-55.

20.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

Supplemental Content

Support Center